Analyst Davides holds a conference call with CEO Chowdhury to discuss the Company’s non-invasive glucose monitoring device, commercial strategy and regulatory progress with the FDA on March 29 at 10 am hosted by EF Hutton. Webcast Link
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NMRD:
- Nemaura Medical participates in a conference call with EF Hutton
- Nemaura includes insulin on list of drugs eligible for EU DuoPack license
- Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement
- Nemaura Medical Announces Receipt of Notice from Nasdaq
- Nemaura Medical receives Nasdaq noncompliance notice